" class="no-js "lang="en-US"> Vial - Medtech Alert
Wednesday, October 02, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Vial | Pharmtech Focus

Vial

About Vial

Vial

Vial is a tech-enabled, next-generation CRO that promises faster, more efficient execution of clinical trials for less. The Vial Preferred Site Network offers a robust investigator community across a wide range of therapeutic areas (Dermatology, Ophthalmology, Oncology, Gastroenterology, Neurology, and Cardiology), connecting dedicated sites to leading sponsors for more streamlined trials that bring new therapies to market faster. Vial is a San Francisco, California-based company with over 125 employees.

Related Story

Diseases

 Vial Announces the Addition of Dr. Marc Hoffmann from the University of Kansas Medical Center to their Oncology CRO Scientific Advisory Board | PTF

Vial Announces the Addition of Dr. Marc Hoffmann from the University of Kansas Medical Center to their Oncology CRO Scientific Advisory Board

November 28 2022

Vial, a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Marc Hoffmann, […]

Clinical Trials

 Vial Has Added NEXT Oncology

Vial Has Added NEXT Oncology, a Global Network of Phase I Cancer Research Centers, to their Preferred Site Network

November 22 2022

Vial has added NEXT Oncology to their Preferred Site Network (PSN). Founded by renowned oncologist Dr. Anthony W. […]